A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene

Ying Cui1, Frederick Hausheer2, Robert Beaty1

  • 1Authors' Affiliations: Cancer Biology Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Cancer Research
|May 31, 2014
PubMed

Insights

Researchers developed a novel gene reporter system to study epigenetic cancer therapies. This system helps understand how reversing gene silencing impacts cancer treatment, offering new insights for drug development and patient care.

Area of Science:

  • Cancer Biology
  • Epigenetics
  • Molecular Oncology

Background:

  • DNA hypermethylation of CpG islands silences tumor-suppressor genes in cancer.
  • Reversing gene silencing presents potential cancer prevention and therapeutic strategies.
  • Enhancing radiotherapy, chemotherapy, or immunotherapy efficacy is a key goal.

Purpose of the Study:

  • To demonstrate a novel gene reporter system for studying epigenetic therapies in colon cancer cells.
  • To investigate the dynamics, mechanisms, and translational relevance of therapies targeting gene silencing.
  • To evaluate the utility of the reporter system in understanding epigenetic cancer drug development.

Main Methods:

  • Developed a reporter system by modifying the endogenous SFRP1 gene locus with GFP in human colon cancer cells.
  • Utilized 5-aza-deoxycitidine (a DNA methyltransferase inhibitor) to test drug-induced gene derepression.
  • Assessed RNA and protein induction, drug exposure duration, and the role of histone deacetylase inhibitors (HDACi).

Main Results:

  • The SFRP1-GFP reporter system remained silent until activated by drug treatments reversing DNA hypermethylation.
  • Clinically relevant dosing of DNA methyltransferase inhibitors (DNMTi) induced sustained RNA and protein expression.
  • Prolonged drug exposure was crucial for effective gene silencing reversal in vivo.
  • Histone deacetylase inhibitors (HDACi) alone could reexpress silenced genes during active DNA replication without altering methylation status.

Conclusions:

  • The novel reporter system provides a powerful tool for studying epigenetic cancer therapies.
  • Findings offer insights into optimizing clinical trials for DNMTi and HDACi, alone or in combination.
  • This approach aids in the epigenetic management and prevention of cancer.

Related Concept Videos